{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1006","value":"2323"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"description":"The mean (sd) of the AUC","dispersionType":"Standard Deviation","groups":[{"description":"Patients receive samotolisib PO BID on days 1-28. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unexpected toxicity. Patients undergo an x-ray, CT, MRI, FDG-PET, and blood sample collection on study.","id":"OG000","title":"Treatment (Samotolisib)"}],"paramType":"MEAN","populationDescription":"Three of the enrolled patients had PK data available for analysis","reportingStatus":"POSTED","timeFrame":"Up to day 15 of cycle 1","title":"Pharmacokinetic (PK) of Samotolisib, Area Under the Curve (AUC).","type":"SECONDARY","unitOfMeasure":"h*μg/mL"}